FDA Assigns Priority Review Status for Sanofi Aventis' Multaq
- Cardio
- 25/08/2008
The priority review is granted to applications in which a new indication or new drug product, if approved, has a potential to present a safe and effective therapy where no satisfactory alternativ
READ MORE